

CuraLife

f curalife

g curalife.com

The Future of Diabetes Care

Diabetes Care is Broken

Traditional treatments have shown poor results in terms of efficacy and safety.

2 out of 3 people with diabetes do not achieve their treatment goals, despite the number of treatment options. This, combined with changing consumer preferences and advancements in digital health technologies offers a unique opportunity to tackle one of the largest healthcare challenges of our times.

THE SAD TRUTH ABOUT TYPE 2 DIABETES

2/3

Don't reach their health targets

463

Million patients diagnosed in 2019

7th

Leading cause of death in 2016

800

Million Prediabetics

Alone in the Dark

The gap in Diabetes Care is not limited to the therapeutic options.

After being diagnosed, type 2 diabetics struggle to find the proper level of knowledge, education and support to cope with a chronic conditions that have implication on multiple aspects of the day-to-day life.

No Knowledge,
No confidence.

Hard access to consumable information increases uncertainty and confusion.

A Lonely
Battle.


The lack of interaction with other people in the same conditions creates desolation.

Nothing beyond
doctors & pills.


Behavioral programs on alimentation, physical activity and mental health carry a crucial role which is almost exclusively avoided in favor of prescribed drugs.

CuraLife

Diabetes Care is about to change. Forever.



AN INNOVATIVE AND ALL-ENCOMPASSING PLATFORM TO MAXIMIZE PATIENT OUTCOMES



CuraLife's unique value fuels global growth. The Diabetes Care Revolution has started.

CuraLife is an Israeli company founded in 2013 and launched commercially in 2017.

At CuraLife's core is an innovative R&D process for developing herbal supplements with unique therapeutic properties.

Every day, people from 50+ countries rely on CuraLife to manage their diabetes.

CuraLife has a strong reputation within the global diabetes medical field. Several exclusive distribution partnerships worldwide facilitate its growth, influence, and value.

Through innovative therapeutics, business models, and patient relationships/management, CuraLife is revolutionizing diabetes care.

CuraLin

Nature's Answer to T2D



Innovative R&D

Powerful combination of science & ayurvedic natural medicine



Synergistic Formulation

Supports key areas that other supplements can't target



Safe, Effective and Visible

Quickly supports healthy blood sugar levels



Strong Clinical Support

Unique efficacy and safety profile shown in clinical studies



CuraLin is a combination of 9 herbal ingredients intended to balance blood glucose levels in diabetic patients and tackle the disease's symptoms to significantly impact patients' overall quality of life. Natural, safe, and effective: type 2 diabetics now have a fantastic new option that delivers results.



WHAT PEOPLE SAY ABOUT CURALIN

76%

REVIEWS.IO



4.8/5

SO TELL US



4.6/5

AMAZON



4.6/5

WALMART



Supported by Global KOLs







Prof. Itamar Raz

M.D - CuraLife's Medical Advisory Board Chairman

Professor Itamar Raz is a world reference in the field of diabetes research. Pr. Raz is currently the most prolific diabetes researcher in the world with 300+ publications.

He also led the largest clinical trial ever performed in the field of diabetes with 16.5K+ patients. He is the head of several associations and institutions, including the National Diabetes Council in Israel, a position appointed by the Minister of Health.

REAL-WORLD DATA ANALYSIS BY PR. RAZ ON 730 CURALIN CLIENTS



YES NO MAYBE

CuraLife Medical Advisory

TOGETHER WE ARE REVOLUTIONIZING DIABETES CARE



Dr. Sarah Brewer

M.Sc (Nutr Med), M.A (Cantab), MB, BChir, RNutr, MBANT



Mr. Amir Malka

Founder & President of BioForum



Dr. Uri Eliyahu

PhD (Epidemiology), M.Sc (Physiology)



Dr. Sara Kaplan

PhD (Clinical Epidemiology)

Clinical Studies

Under the leadership of Pr. Raz and other global experts and institutions, CuraLife invests significantly in clinical studies. Two double-blind placebo-controlled are currently running. Additional information can be provided upon request.